Royalty Pharma PLC $RPRX Position Trimmed by Cooper Investors PTY Ltd.

Cooper Investors PTY Ltd. decreased its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 22.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 164,249 shares of the biopharmaceutical company’s stock after selling 47,572 shares during the quarter. Royalty Pharma comprises 4.2% of Cooper Investors PTY Ltd.’s holdings, making the stock its 8th biggest position. Cooper Investors PTY Ltd.’s holdings in Royalty Pharma were worth $9,209,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. LM Advisors LLC purchased a new stake in shares of Royalty Pharma during the fourth quarter valued at $26,000. Lloyd Advisory Services LLC. purchased a new position in Royalty Pharma in the 4th quarter worth $30,000. Private Trust Co. NA raised its stake in Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 288 shares during the last quarter. Blue Trust Inc. raised its stake in Royalty Pharma by 173.4% in the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 437 shares during the last quarter. Finally, CIBC Private Wealth Group LLC lifted its position in Royalty Pharma by 66.4% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 446 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Insider Buying and Selling

In related news, EVP Marshall Urist sold 9,099 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $55.88, for a total transaction of $508,452.12. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of Royalty Pharma stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $56.52, for a total transaction of $5,652,000.00. Following the completion of the transaction, the executive vice president directly owned 459,399 shares of the company’s stock, valued at $25,965,231.48. The trade was a 17.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 393,009 shares of company stock worth $21,601,827. 18.84% of the stock is currently owned by company insiders.

Royalty Pharma Price Performance

NASDAQ:RPRX opened at $57.48 on Wednesday. The firm’s fifty day moving average is $56.32 and its two-hundred day moving average is $50.17. The firm has a market cap of $33.10 billion, a price-to-earnings ratio of 39.10, a PEG ratio of 10.13 and a beta of 0.43. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.66 and a current ratio of 2.66. Royalty Pharma PLC has a one year low of $34.08 and a one year high of $60.44.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. The business had revenue of $630.58 million during the quarter, compared to analyst estimates of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. Research analysts expect that Royalty Pharma PLC will post 5.18 EPS for the current year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a $0.235 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.94 dividend on an annualized basis and a yield of 1.6%. Royalty Pharma’s payout ratio is presently 63.95%.

Wall Street Analysts Forecast Growth

RPRX has been the topic of several research analyst reports. JPMorgan Chase & Co. boosted their price target on Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Citigroup raised their price objective on Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. UBS Group lifted their target price on Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday, April 21st. Wall Street Zen upgraded Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, TD Cowen increased their price target on shares of Royalty Pharma from $50.00 to $65.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Seven research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $56.57.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.